1. Home
  2. LSAK vs RVNC Comparison

LSAK vs RVNC Comparison

Compare LSAK & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSAK
  • RVNC
  • Stock Information
  • Founded
  • LSAK 1997
  • RVNC 1999
  • Country
  • LSAK South Africa
  • RVNC United States
  • Employees
  • LSAK N/A
  • RVNC N/A
  • Industry
  • LSAK Investment Bankers/Brokers/Service
  • RVNC Biotechnology: Pharmaceutical Preparations
  • Sector
  • LSAK Finance
  • RVNC Health Care
  • Exchange
  • LSAK Nasdaq
  • RVNC Nasdaq
  • Market Cap
  • LSAK N/A
  • RVNC 292.5M
  • IPO Year
  • LSAK N/A
  • RVNC 2014
  • Fundamental
  • Price
  • LSAK $4.96
  • RVNC $3.64
  • Analyst Decision
  • LSAK
  • RVNC Buy
  • Analyst Count
  • LSAK 0
  • RVNC 9
  • Target Price
  • LSAK N/A
  • RVNC $12.00
  • AVG Volume (30 Days)
  • LSAK 44.3K
  • RVNC 2.0M
  • Earning Date
  • LSAK 09-10-2024
  • RVNC 08-06-2024
  • Dividend Yield
  • LSAK N/A
  • RVNC N/A
  • EPS Growth
  • LSAK N/A
  • RVNC N/A
  • EPS
  • LSAK N/A
  • RVNC N/A
  • Revenue
  • LSAK $551,325,000.00
  • RVNC $236,645,000.00
  • Revenue This Year
  • LSAK $9.63
  • RVNC $20.63
  • Revenue Next Year
  • LSAK $8.35
  • RVNC $34.80
  • P/E Ratio
  • LSAK N/A
  • RVNC N/A
  • Revenue Growth
  • LSAK 6.72
  • RVNC 54.59
  • 52 Week Low
  • LSAK $3.00
  • RVNC $2.30
  • 52 Week High
  • LSAK $5.33
  • RVNC $24.87
  • Technical
  • Relative Strength Index (RSI)
  • LSAK 60.42
  • RVNC 60.00
  • Support Level
  • LSAK $4.76
  • RVNC $3.56
  • Resistance Level
  • LSAK $4.84
  • RVNC $4.38
  • Average True Range (ATR)
  • LSAK 0.13
  • RVNC 0.30
  • MACD
  • LSAK 0.02
  • RVNC 0.13
  • Stochastic Oscillator
  • LSAK 89.19
  • RVNC 62.53

About RVNC Revance Therapeutics Inc.

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Share on Social Networks: